Norak Biosciences has signed a second technology licensing agreement with Astra Zeneca for drug development.
AstraZeneca will use Norak’s Transfluor technology in researching of several potential drug compounds. The companies began doing business together in 2002.
The new agreement covers the further development of compounds advanced already by AstraZeneca using Norak technology.
Norak: www.norakbio.com
